Navigation Links
VaxGen Addresses MPM Claims in Letter to Stockholders
Date:12/20/2007

ifies the VaxGen manufacturing facility as an important asset with unrealized financial value. VaxGen has broadly marketed this manufacturing facility for the past 11 months, using multiple agents and resources, including VaxGen's financial advisors, Lazard & Co., management and two sets of consultants. This process is still underway with the objective of selling or leasing the facility as an operating asset, but no offers have been received to date.

In arriving at a realistic valuation for the manufacturing plant, it is important to understand that this facility is located within a leased building, so the land and building do not contribute to potential sale value. This is a point that has clearly been misunderstood by some stockholders. Further, the sale of the facility as part of a liquidation proceeding rather than as an operating facility, would likely deliver minimal value to stockholders. Most commonly, sale of equipment in liquidation yields only a small fraction of book value for such assets. Secondly, the leased building would have to be returned to its previous condition, which is likely to consume most if not all of the proceeds from an equipment sale. Therefore, VaxGen feels that it will be more likely to deliver stockholder value from this asset as part of the Raven merger, and potential third party transactions, than through a liquidation of this asset.

Turning to the anthrax program: As with the plant, VaxGen has engaged in a broad marketing effort to sell or out-license this program. We have used a former vaccine industry executive as an agent, in addition to the efforts of management and Lazard, to identify interested companies. More than two dozen companies, including all relevant pharmaceutical and vaccine companies have been contacted to identify interest in purchasing or partnering the rPA program. No credible offers have been received for the program to date, and our efforts to sell this asset continue.

While VaxGen is con
'/>"/>

SOURCE VaxGen
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. VaxGen Files 2006 Financial Statements and Provides Cash Update
2. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
3. VaxGen Files First Quarter 2007 Financials
4. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
5. VaxGen Files Last Outstanding Periodic Report With SEC
6. Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers
7. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
8. European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
9. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
10. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
11. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
(Date:8/31/2014)... This is a professional and ... Epoxy Hardener industry in Global and China. ... industry, including definitions, applications and industry chain structure. ... are provided with a focus on history, developments, ... comparison between the international and Chinese situation is ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Lentigen Corporation, a biotechnology company specializing in the ... and Expression Therapeutics, a biotechnology company specializing in ... to co-develop novel cell and protein therapies for ... disorder caused by a mutation in the factor ...
... Kendle (Nasdaq: KNDL ) announced today that ... the market closes on Tuesday, Feb. 24, 2009. The Company ... Wednesday, Feb. 25 at 8:30 a.m. Eastern Time. A question ... , To participate in the telephone conference call, interested parties ...
... Feb. 4 On the heels of a strong start ... executives will explain to investors this month where the company ... this year and how it plans to achieve its goal ... by fiscal 2012. Terry Crews, chief financial officer, and Carl ...
Cached Biology Technology:Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 2Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Monsanto Executives to Discuss Company's Growth Drivers, Profit Goals at Investor Conferences in February 2
(Date:9/1/2014)... how the alteration of a single nucleotidethe basic building block of ... intellectual disability. The study appears in The Journal of ... caused by a defect in a gene on the X chromosome ... in 230 women and 1 in 360 men carry a so-called ... of the FMR1 gene is slightly longer than normal. ...
(Date:8/31/2014)... University of Warwick have discovered that ,good, cholesterol is ... substance, methylglyoxal - MG, was found to damage ,good, ... from the body. , Low levels of HDL, ... with increased levels of MG being common in the ... , Supported by funding from the British Heart Foundation ...
(Date:8/31/2014)... busy attacking us, germs go after each other. But ... for the infected microbes: Sometimes viruses actually carry helpful ... its diet or better attack its own hosts. , ... system would robotically destroy anything it recognized as invading ... now revealed that one variety of the bacterial immune ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Sugar substance 'kills' good HDL cholesterol, new research finds 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... & EMS Management Software Provider to Offer Biometrics, ... award-winning,fingerprint biometrics research and development firm, announced today ... Data Systems(R), an,industry leader in the development of ... software and hardware to ZOLL Data,Systems, customers., ...
... 10, 2008 -- The National Institutes of Health (NIH) ... College Assistant Professor of Biology Lara D. Hutson, in ... CMT is the most common inherited neuromuscular disease, ... CMT usually shows dominant inheritance and symptoms generally appear ...
... Human cancer cells divide and conquer. Unless physicians can ... wildly dividing cells will eventually destroy a person,s life. ... an enzyme called telomerase is crucial to cancer,s progress. ... of Georgia,s Franklin College of Arts and Sciences have ...
Cached Biology News:M2SYS Technology Selected by ZOLL Data Systems to Integrate Fingerprint Software 2UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: